Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Short-term Investments (2023 - 2026)

Beta Bionics' Short-term Investments history spans 4 years, with the latest figure at $100000.0 for Q1 2026.

  • On a quarterly basis, Short-term Investments fell 99.95% to $100000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $100000.0, a 99.95% decrease, with the full-year FY2025 number at $187.5 million, up 156.41% from a year prior.
  • Short-term Investments hit $100000.0 in Q1 2026 for Beta Bionics, down from $187.5 million in the prior quarter.
  • Over the last five years, Short-term Investments for BBNX hit a ceiling of $214.6 million in Q2 2025 and a floor of $100000.0 in Q1 2026.
  • Historically, Short-term Investments has averaged $132.1 million across 4 years, with a median of $187.5 million in 2025.
  • Biggest five-year swings in Short-term Investments: surged 156.41% in 2025 and later tumbled 99.95% in 2026.
  • Tracing BBNX's Short-term Investments over 4 years: stood at $70.2 million in 2023, then rose by 4.22% to $73.1 million in 2024, then surged by 156.41% to $187.5 million in 2025, then plummeted by 99.95% to $100000.0 in 2026.
  • Business Quant data shows Short-term Investments for BBNX at $100000.0 in Q1 2026, $187.5 million in Q4 2025, and $190.2 million in Q3 2025.